New drug daraxonrasib has shown surprising survival gains in advanced pancreatic cancer and could reshape treatment for other tumors driven by the KRAS mutation, offering fresh hope where options have been painfully limited.
A personal story opens this piece: a vibrant woman in her mid-40s received a pancreatic cancer diagnosis and was given only months to live. She lived five months after that grim timetable, and her experience underscores how brutal pancreatic cancer can be when it is diagnosed late and has already spread.
Pancreatic cancer remains one of the deadliest cancers, often slipping past detection until it has metastasized. New clinical data now suggest daraxonrasib can extend survival substantially in patients with advanced disease, a result that has caught the attention of oncologists and patients alike.
Enthusiasm around daraxonrasib is reaching a fever pitch. In the phase 3 trial of 500 patients, the drug was shown to double the survival time of patients with advanced pancreatic cancer, a notoriously deadly cancer: 13.2 months, on average, compared to 6.7 months for people who got chemo. On Sunday, Wainberg and his colleagues presented those results at the American Society of Clinical Oncology’s annual meeting in Chicago. The full study was simultaneously published in the New England Journal of Medicine.
When Revolution Medicines, which makes the drug, released the trial’s preliminary findings in April, Dr. Rachna Shroff, chief of the division of hematology and oncology at the University of Arizona Cancer Center in Tucson, said she “started crying tears of joy.”
“It’s that big of a game-changer for those of us who treat pancreatic cancer,” she said. “It’s unprecedented.”
The basic science behind the result is straightforward and elegant: daraxonrasib is designed to hit a specific genetic driver that fuels many aggressive cancers. That target is the KRAS mutation, which acts like an on/off switch for cell growth and is stuck in the on position in the majority of pancreatic tumors.
Daraxonrasib targets a mutation in a gene called KRAS, which works like an on/off switch controlling how cells grow in the body. The mutation, which is found in more than 90% of pancreatic cancers, causes the switch to get stuck in an “on” position, allowing cancer cells to grow wildly out of control.
Scientists have known for years that if they could target the KRAS mutation, they could wrench that switch from its “on” position.
“It’s been incredibly hard to drug that mutation,” Wolpin said. “That mutated protein is like a round ball, and you just can’t get the drug to stick to it, to block the effect.” It’s only “through some really amazing chemistry work,” he said, that scientists have been able to develop a drug to work on the mutation.
Daraxonrasib is that first drug. It works by pairing up with a protein called cyclophilin A inside cells, acting like a “molecular glue,” Wolpin said, glomming onto the mutated protein.
That molecular-glue approach is novel: rather than forcing a slip into a tight pocket on an awkwardly shaped protein, the drug links the mutant KRAS to another cellular protein to stop its runaway signaling. It’s a different tactic from old-school chemotherapy, and it appears to translate into meaningful survival gains in this trial.
Beyond pancreatic cancer, the KRAS mutation shows up in multiple tumor types, so the implications are wider than a single diagnosis. Colorectal cancer, non-small cell lung cancer, bile tract tumors, several gynecologic cancers, and even some testicular germ cell cancers can harbor KRAS-driven pathways that might respond to this kind of therapy.
For patients and families who have faced the worst prognoses, a drug that doubles median survival from months to more than a year is more than a statistic. It shifts conversations about treatment options, quality of life, and what hopeful progress looks like in a disease area where hope has been scarce.
Medical advances rarely deliver instant cures, and daraxonrasib is not a silver bullet. Still, the phase 3 results suggest it could become a powerful tool in oncologists’ hands and a real difference-maker for patients who had few alternatives.
Clinical practice will depend on follow-up data, access, and how well the treatment integrates with existing regimens, but the early evidence makes a strong case for continued study and careful rollout. Patients, families, and clinicians should watch this space as more data emerge and as researchers test the drug in other KRAS-driven cancers.
Add comment